Bain Capital in Talks to Acquire PCI Pharma Services for Over $10 Billion

It has recently been reported by Bloomberg, citing sources familiar with the matter, that global private equity giant Bain Capital is in talks to acquire PCI Pharma Services (hereinafter referred to as “PCI Pharma”), a globally renowned contract development and manufacturing organization (CDMO). This potential acquisition could become one of the largest private equity deals of the year.

The report also stated that Bain Capital is negotiating with PCI Pharma’s existing investors, including Kohlberg & Co., Mubadala Investment Co., and Partners Group Holding AG. The proposed transaction is reportedly valued at over $10 billion, including debt.

According to sources, an announcement regarding the transaction could be released in the coming weeks. However, Bloomberg also noted that ongoing market volatility and broader macroeconomic uncertainty could disrupt negotiations, ultimately leaving PCI Pharma Services under its current ownership.

Representatives from Bain Capital, Kohlberg, Mubadala, Partners Group, and PCI all declined to comment.

In fact, not long ago, PCI Pharma Services completed its acquisition of Ajinomoto Althea (hereinafter referred to as “Althea”) as part of its $1 billion investment strategy. Althea is a U.S.-based contract development and manufacturing organization (CDMO) specializing in sterile fill-finish services and is a subsidiary of Japan’s Ajinomoto Co., Inc. This acquisition represents a key component of PCI’s multi-year investment strategy for its facilities in the United States and Europe.

It is reported that in the United States, Althea’s assets will be integrated with PCI Pharma Services’ existing sterile fill-finish and advanced drug delivery systems businesses to create a world-class large-scale manufacturing site in San Diego. This facility will feature a state-of-the-art large-scale sterile fill-finish plant dedicated to the production of pre-filled syringes and cartridges. Notably, Althea specializes in customized, scalable oligonucleotide and peptide manufacturing, which will enhance PCI’s existing capabilities in complex formulations and lyophilization processes, covering a wide range of injectable dosage forms including nanoparticles, mRNA, monoclonal antibodies, proteins, and other biologics.

In fact, this acquisition also added high-potency vial filling and lyophilization capabilities. This move not only expanded PCI Pharma’s sterile filling capacity but also enabled it to efficiently enter the rapidly emerging field of oncology therapeutics—specifically, the production of antibody-drug conjugates (ADCs). In other words, this acquisition has positioned PCI Pharma as one of the few contract development and manufacturing organizations (CDMOs) in the United States with ADC filling capabilities.

In line with its development strategy, PCI Pharma Services began expanding into the antibody-drug conjugate (ADC) sector in early 2025, establishing an advanced new drug development laboratory at its Center of Excellence in Bedford, New Hampshire, for the production of active and inactive compounds. The expansion of the sterile fill-finish facility in Bedford commenced with significant investment in dedicated infrastructure and is expected to achieve Good Manufacturing Practice (GMP) certification in the second quarter of 2025.

PCI Pharma is indeed known as an “expansion maniac” in the CDMO sector.

As early as 2020, PCI Pharma announced the acquisition of Bellwyck Pharma Services, headquartered in Toronto, Canada. Bellwyck is a leader in primary and secondary packaging and labeling for clinical trial and commercial pharmaceutical products. Through this acquisition, PCI Pharma added four GMP-compliant facilities to its network in the United States, Germany, and Canada, thereby enhancing its influence in the global market.

In December of the same year, PCI Pharma Services, a provider of outsourced solutions for pharmaceutical and biopharmaceutical services, announced the completion of its acquisition by Kohlberg & Company, which acquired a majority stake. This move aims to expand specialized manufacturing capacity and further extend its geographic presence in Asia and Europe.

In 2021, PCI Pharma acquired its peer, Lyophilization Services of New England, Inc. (hereinafter referred to as “LSNE”), aiming to expand PCI Pharma’s service offerings as a global CDMO and strengthen its expertise in biologic packaging and specialized manufacturing. Subsequently, PCI Pharma announced a new milestone for its global clinical operations: the expansion of cold-chain clinical supply storage and distribution capabilities at its Berlin facility, thereby providing regional clients with global access.

In 2022, PCI Pharma announced a major expansion of its world-class facility in Wales, UK, aimed at supporting business growth in targeted oncology therapies, which were then a core strength of PCI Pharma. The expansion included two new facilities dedicated to the manufacturing and packaging of solid oral tablets and capsules.

In 2023, PCI Pharma Services continued its momentum, first investing $50 million to construct a new 200,000-square-foot production facility at its campus in Rockford, Illinois, and later announcing the addition of three advanced automated aseptic filling lines in San Diego and Melbourne. These innovative systems can fill various sterile drugs into vials and syringes, catering to the needs of small and mid-sized clients. When combined with PCI’s end-to-end services, they significantly reduce the turnaround time from contract signing to the supply of injectable products.

However, it should be noted that the aforementioned acquisitions were inevitable steps for PCI Pharma Services in advancing its capabilities in advanced drug delivery systems, including pre-filled syringes, cartridges, and auto-injectors. In 2024, PCI Pharma Services announced an investment of over $365 million to support clinical and commercial-scale final assembly and packaging of drug-device combination products utilizing advanced drug delivery systems, with a focus on injectable formulations. This initiative includes constructing new facilities and expanding existing infrastructure in the United States and Europe, thereby enhancing PCI’s ability to manage the full lifecycle of drug-device combinations (DDCs).

This M&A announcement inevitably recalls the premium acquisition in 2024: GHO Capital Partners LLP (“GHO”) and Ampersand Capital Partners (“Ampersand”) announced that they had entered into a definitive merger agreement with CDMO company Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid”). Under the terms of the deal, GHO and Ampersand will acquire all outstanding shares held by Avid’s shareholders for $12.50 per share in cash, implying an enterprise value of approximately $1.1 billion (about RMB 7.8 billion), which represents 6.3 times Avid’s projected revenue for fiscal year 2025.

Avid and PCI Pharma Services share a striking similarity in that both have been closely aligned with market development since their inception. In the early stages, both companies actively expanded and perfected their hardware infrastructure; in the mid-to-late stages (with Avid doing so after its IPO), they closely followed trends in the innovative drug industry and flexibly broadened their business scope by capitalizing on market hotspots.

A Contract Development and Manufacturing Organization (CDMO) is an institution that provides customized research, development, and manufacturing services to pharmaceutical and biotechnology companies. These services encompass process development and manufacturing for pharmaceuticals—particularly innovative drugs—process optimization and scale-up production, regulatory filing and validation batch production, as well as commercial-scale manufacturing. During periods of industry prosperity, the biomedical sector has emerged as a lucrative frontier in the new era, presenting numerous opportunities, while CDMOs have achieved rapid growth alongside industrial development. From 2017 to 2021, the global CDMO market size expanded from $39.4 billion to $63.2 billion, representing a compound annual growth rate (CAGR) of 12.5%. It can be said that the expansions of both Avid and PCI Pharma Services coincided precisely with this wave of growth. Notably, Novo Nordisk, once constrained by “capacity bottlenecks,” outsourced the assembly and secondary packaging of its injection pens to PCI Pharma Services—a product line central to Novo Nordisk’s highly successful GLP-1 business segment.

However, public sentiment toward the CDMO sector has been less than positive from 2023 to the present. In recent years, the CDMO industry has undergone significant transformations, including expansion of the global market size, shifts in geographic distribution, upgrades in business models, and iterations of new technologies. With Catalent’s acquisition, Lonza’s closure of its biotechnology facility in Guangzhou Knowledge City within the Guangzhou Development District, and the looming crisis of overcapacity—compounded by regional development dynamics—the CDMO industry now stands at a critical inflection point between boom and bust, seeking new pathways forward.

Therefore, only CDMOs that have a backlog of orders, can rapidly expand production capacity and pursue growth through mergers and acquisitions, and seize the development opportunities arising from the innovative drug boom to turn them into profitable “weapons” will be able to break through quickly.

This may be what has caught Bain Capital’s attention. As early as February 7, 2025, Bain Capital began its strategic moves by announcing an agreement with Mitsubishi Chemical Group to acquire its subsidiary, Mitsubishi Tanabe Pharma Corporation (MTPC), for ¥510 billion (approximately $3.3 billion), setting a record for the largest merger and acquisition deal in the Asian pharmaceutical industry at the start of 2025. Should this current $10 billion acquisition go through, it will mark another new milestone in Bain Capital’s global strategy.